ASOS plc/ GB0030927254 /
2024-10-03 3:30:00 PM | Chg. - | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
5.4100USD | - | 1,666 Turnover: 9,013.0600 |
-Bid Size: - | -Ask Size: - | 5.4100 | 5.4100 |
GlobeNewswire
08-14
Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
08-14
Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potent...
GlobeNewswire
08-07
Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
08-07
Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Pr...
GlobeNewswire
08-06
Loqate names HERE Technologies foundational partner supporting address verification for e-commerce a...
GlobeNewswire
06-24
Matinas BioPharma Reports Successful Treatment of Patient with Limb-Threatening Mucor Infection in i...
GlobeNewswire
06-13
Matinas BioPharma’s Oral MAT2203 to Be Featured in Fireside Chat Hosted by A.G.P. with Antifungal Ex...
GlobeNewswire
05-16
New In Vitro Data Showing Matinas BioPharma’s LNC Platform Delivering Small Oligonucleotides Present...
GlobeNewswire
05-09
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
05-07
Creyon Bio to Present Clinical Data on Rapid AI-Enabled Engineering of Oligonucleotide-Based Medicin...
GlobeNewswire
05-07
Matinas BioPharma’s LNC Platform for the Delivery of Small Oligonucleotides Featured in Two Presenta...
GlobeNewswire
05-02
Matinas BioPharma to Webcast Conference Call to Discuss First Quarter 2024 Financial Results and Pro...
GlobeNewswire
05-01
Creyon Bio and Cajal Neuroscience Announce Partnership to Develop Oligonucleotide-Based Medicines fo...
GlobeNewswire
04-30
In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal ...
GlobeNewswire
03-25
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
GlobeNewswire
03-22
Three Patients with Invasive Fusarium Infection in Matinas BioPharma’s Oral MAT2203 Compassionate/Ex...
GlobeNewswire
03-22
Matinas BioPharma Regains Compliance with NYSE American Continued Listing Standards
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
02-26
Matinas BioPharma Provides Positive Outcomes Update on the MAT2203 Compassionate/Expanded Use Access...